Home/Indications/Skin and Skin Structure Infections

Skin and Skin Structure Infections

0 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Skin and Skin Structure Infections has 0 FDA-approved novel treatments across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Skin and Skin Structure Infections Treatments by Mechanism

Top 1 mechanisms across 1 industry trials with a known mechanism of action.

See full pipeline →

Lipopeptide Antibacterial

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Skin and Skin Structure Infections Clinical Pipeline by Phase

20 industry-sponsored trials across 14 sponsors

Showing 3 of 3 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AbbVie	Usual Care	—	COMPLETED	2019-03-29	NCT02961764
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Daptomycin	Lipopeptide Antibacterial [EPC]	COMPLETED	2012-09-01	NCT01419184
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Vancomycin	—	TERMINATED	2012-06-12	NCT01104662

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AbbVie	Dalbavancin	—	COMPLETED	2024-01-01	NCT02814916
Merck	Tedizolid phosphate	—	COMPLETED	2023-07-06	NCT03176134
Basilea Pharmaceutica	ceftobiprole medocaril	—	COMPLETED	2019-04-22	NCT03137173
Wockhardt	Oral Levonadifloxacin/Linezolid Tablet	—	COMPLETED	2018-09-25	NCT03405064
Arrevus Inc.	sodium fusidate	—	COMPLETED	2016-11	NCT02570490
Stiefel, a GSK Company	Retpamulin Ointment, 1%	—	COMPLETED	2010-07	NCT00852540
GSK	Retapamulin Ointment, 1%	—	COMPLETED	2009-10	NCT00684177

Showing 6 of 6 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Lytix Biopharma AS	LTX-109	—	COMPLETED	2011-02	NCT01223222
GSK	GSK1322322	—	COMPLETED	2011-01-18	NCT01209078
Furiex Pharmaceuticals, Inc	JNJ-32729463	—	COMPLETED	2010-12	NCT01128530
Novexel Inc	NXL103	—	COMPLETED	2010-03	NCT00949130
Protez Pharmaceuticals, Inc.	PZ-601	—	COMPLETED	2009-02	NCT00671580
Melinta Therapeutics, Inc.	delafloxacin	—	COMPLETED	2008-10	NCT00719810

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
GSK	Retapamulin Microdialysis	—	COMPLETED	2014-05-27	NCT01812382
GSK	Isotretinoin 40 mg	—	COMPLETED	2011-09-23	NCT01863615
GSK	Minocycline 100mg	—	COMPLETED	2011-06-25	NCT01755611
Pfizer	SA3Ag vaccine	—	COMPLETED	2011-01	NCT01018641

Novel Skin and Skin Structure Infections Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (11 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

CEFAZOLIN IN DEXTROSE

Baxter

T5 2015

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL

T4 2015